Iodure (123i) De Sodium Ge Healthcare (Sodium Iodide (123 I))

Sodium Iodide in Iodure (123i) is labeled with the gamma‑emitting isotope iodine‑123. After intravenous injection, it is actively transported into cells that express the sodium‑iodide symporter, especially thyroid follicular cells and some cardiac myocytes. The emitted gamma photons are detected by a gamma camera, producing high‑resolution images that reflect the physiological activity of the targeted tissues.

The administered activity of Iodure (123i) is determined by the prescribing physician based on the specific diagnostic protocol, patient size, and the imaging equipment used. Dosing is expressed in megabecquerels (MBq) and is calculated to provide sufficient image quality while keeping radiation exposure as low as reasonably achievable.

Iodure (123i) is generally avoided in pregnant or breastfeeding women because the iodine‑123 radiation can cross the placenta and be secreted in breast milk, potentially exposing the fetus or infant to ionizing radiation. Use is only considered if the diagnostic benefit outweighs the potential risk and after thorough risk assessment by the healthcare provider.

To order Iodure (123i), submit an enquiry on the product page at gnhindia.com indicating the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide, and will request verification of trade or institutional credentials. After confirmation, the team provides pricing, availability, shipping details—including any cold‑chain requirements—and assists with import documentation.

The main alternative to Iodure (123i) is iodine‑131 sodium iodide, which emits both beta and gamma radiation and delivers a higher radiation dose. Iodine‑123 provides superior image quality with lower radiation exposure. Another common agent is technetium‑99m pertechnetate, which does not require a sodium‑iodide symporter for uptake but offers less specific thyroid imaging compared with I‑123 sodium iodide.

Iodure (123i) must be stored at 2‑8 °C in a refrigerator, protected from light. The vial should remain in its original packaging, should not be frozen, and must be handled gently to avoid agitation. Before use, verify that the product is within its expiry date and that the cold‑chain integrity has been maintained during transport.

Iodure (123i) is administered as a single intravenous injection. The radiopharmaceutical is drawn from the vial using aseptic technique and injected into a peripheral vein. After administration, patients may be monitored for a short period to observe any immediate reactions before proceeding with the imaging procedure.

The most serious risks include severe allergic reactions such as anaphylaxis, marked hypotension that may require medical intervention, cardiac arrhythmias in susceptible individuals, and radiation‑induced thyroiditis. Additionally, inadvertent exposure of a pregnant woman or fetus to iodine‑123 can pose significant radiation risks, underscoring the need for careful patient selection.

Iodure (123i) should not be used in patients with a known hypersensitivity to iodine or radiopharmaceuticals, pregnant or breastfeeding women unless absolutely necessary, individuals with severe renal impairment that could affect clearance, and patients who have received other radioactive iodine agents or iodinated contrast media within the preceding weeks, as these conditions can interfere with tracer uptake and safety.